Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems

Bibliography

• Zhou S, Chan E, Pan SQ, Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 2004;18(2):262-76
   PubMed Web of Science ®Google Scholar
• Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61(3):246-55
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31(7):815-32
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Suzuki A, Kohno Y. High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method. Xenobiotica 2004;34(1):87-101
   PubMed Web of Science ®Google Scholar
• White RE. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol 2000;40:133-57
   PubMed Web of Science ®Google Scholar
• Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59(1):7-13
   PubMed Web of Science ®Google Scholar
• Lee CR, Thrasher KA. Difficulties in anticoagulation management during coadministration of warfarin and rifampin. Pharmacotherapy 2001;21(10):1240-6
   PubMed Web of Science ®Google Scholar
• Ferslew KE, Hagardorn AN, Harlan GC, McCormick WF. A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci 1998;43(5):1082-5
   PubMed Web of Science ®Google Scholar
• Kudo K, Imamura T, Jitsufuchi N, Death attributed to the toxic interaction of triazolam, amitriptyline and other psychotropic drugs. Forensic Sci Int 1997;86(1-2):35-41
   PubMed Web of Science ®Google Scholar
• Yao C, Levy RH. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J Pharm Sci 2002;91(9):1923-35
   PubMed Web of Science ®Google Scholar
• Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 2007;46(8):681-96
   PubMed Web of Science ®Google Scholar
• Zhou C, Assem M, Tay JC, Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 2006;116(6):1703-12
   PubMed Web of Science ®Google Scholar
• Dickins M. Induction of cytochromes P450. Curr Top Med Chem 2004;4(16):1745-66
   PubMed Web of Science ®Google Scholar
• Lin JH. CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 2006;23(6):1089-116
   PubMed Web of Science ®Google Scholar
• Gelboin HV. Benzo[alpha]pyrene metabolism, activation and carcinogenesis: role and regulation of mixed-function oxidases and related enzymes. Physiol Rev 1980;60(4):1107-66
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35(5):361-90
   PubMed Web of Science ®Google Scholar
• Hollenberg PF. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev 2002;34(1-2):17-35
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K, In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 2005;78(6):582-92
   PubMed Web of Science ®Google Scholar
• Grime KH, Bird J, Ferguson D, Riley RJ. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci 2009;36(2-3):175-91
   PubMed Web of Science ®Google Scholar
• Hisaka A, Ohno Y, Yamamoto T, Suzuki H . Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacol Ther 2010;125(2):230-48
   PubMed Web of Science ®Google Scholar
• Watkins PB, Wrighton SA, Schuetz EG, Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture. J Biol Chem 1986;261(14):6264-71
   PubMed Web of Science ®Google Scholar
• Ryu DY, Levi PE, Hodgson E. Regulation of hepatic CYP1A isozymes by piperonyl butoxide and acenaphthylene in the mouse. Chem Biol Interact 1997;105(1):53-63
   PubMed Web of Science ®Google Scholar
• Ryu DY, Levi PE, Fernandez-Salguero P, Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver. Mol Pharmacol 1996;50(3):443-6
   PubMed Web of Science ®Google Scholar
• Raffalli-Mathieu F, Glisovic T, Ben-David Y, Lang MA. Heterogeneous nuclear ribonucleoprotein A1 and regulation of the xenobiotic-inducible gene Cyp2a5. Mol Pharmacol 2002;61(4):795-9
   PubMed Web of Science ®Google Scholar
• Song BJ, Matsunaga T, Hardwick JP, Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat. Mol Endocrinol 1987;1(8):542-7
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Moore JT, Wade L, An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998;92(1):73-82
   PubMed Web of Science ®Google Scholar
• Bertilsson G, Heidrich J, Svensson K, Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 1998;95(21):12208-13
   PubMed Web of Science ®Google Scholar
• Baes M, Gulick T, Choi HS, A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol Cell Biol 1994;14(3):1544-52
   PubMed Web of Science ®Google Scholar
• Whitlock JP Jr. Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 1999;39:103-25
   PubMed Web of Science ®Google Scholar
• Handschin C, Meyer UA. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch Biochem Biophys 2005;433(2):387-96
   PubMed Web of Science ®Google Scholar
• Reschly EJ, Krasowski MD. Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Curr Drug Metab 2006;7(4):349-65
   PubMed Web of Science ®Google Scholar
• Hukkanen J, Vaisanen T, Lassila A, Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther 2003;304(2):745-52
   PubMed Web of Science ®Google Scholar
• Wang H, Faucette SR, Gilbert D, Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes. Drug Metab Dispos 2003;31(5):620-30
   PubMed Web of Science ®Google Scholar
• Higashi E, Fukami T, Itoh M, Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos 2007;35(10):1935-41
   PubMed Web of Science ®Google Scholar
• Jones SA, Moore LB, Shenk JL, The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 2000;14(1):27-39
   PubMed Web of Science ®Google Scholar
• Stanley LA, Horsburgh BC, Ross J, PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab Rev 2006;38(3):515-97
   PubMed Web of Science ®Google Scholar
• Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev 2003;55(4):649-73
   PubMed Web of Science ®Google Scholar
• El-Sankary W, Gibson GG, Ayrton A, Plant N. Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 2001;29(11):1499-504
   PubMed Web of Science ®Google Scholar
• Luo G, Cunningham M, Kim S, CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002;30(7):795-804
   PubMed Web of Science ®Google Scholar
• Watkins RE, Wisely GB, Moore LB, The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 2001;292(5525):2329-33
   PubMed Web of Science ®Google Scholar
• Timsit YE, Negishi M. CAR and PXR: the xenobiotic-sensing receptors. Steroids 2007;72(3):231-46
   PubMed Web of Science ®Google Scholar
• Ung CY, Li H, Yap CW, Chen YZ. In silico prediction of pregnane X receptor activators by machine learning approaches. Mol Pharmacol 2007;71(1):158-68
   PubMed Web of Science ®Google Scholar
• Ekins S, Kortagere S, Iyer M, Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR. PLoS Comput Biol 2009;5(12):e1000594
   PubMed Web of Science ®Google Scholar
• Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 2003;42(15):1331-57
   PubMed Web of Science ®Google Scholar
• Koyano S, Kurose K, Saito Y, Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab Dispos 2004;32(1):149-54
   PubMed Web of Science ®Google Scholar
• Kawana K, Ikuta T, Kobayashi Y, Molecular mechanism of nuclear translocation of an orphan nuclear receptor, SXR. Mol Pharmacol 2003;63(3):524-31
   PubMed Web of Science ®Google Scholar
• Squires EJ, Sueyoshi T, Negishi M. Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver. J Biol Chem 2004;279(47):49307-14
   PubMed Web of Science ®Google Scholar
• Hariparsad N, Chu X, Yabut J, Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes. Nucleic Acids Res 2009;37(4):1160-73
   PubMed Web of Science ®Google Scholar
• Lehmann JM, McKee DD, Watson MA, The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102(5):1016-23
   PubMed Web of Science ®Google Scholar
• Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 1999;56(6):1329-39
   PubMed Web of Science ®Google Scholar
• Goodwin B, Redinbo MR, Kliewer SA. Regulation of cyp3a gene transcription by the pregnane x receptor. Annu Rev Pharmacol Toxicol 2002;42:1-23
   PubMed Web of Science ®Google Scholar
• Liu FJ, Song X, Yang D, The far and distal enhancers in the CYP3A4 gene co-ordinate the proximal promoter in responding similarly to the pregnane X receptor but differentially to hepatocyte nuclear factor-4alpha. Biochem J 2008;409(1):243-50
   PubMedGoogle Scholar
• Dolwick KM, Schmidt JV, Carver LA, Cloning and expression of a human Ah receptor cDNA. Mol Pharmacol 1993;44(5):911-7
   PubMed Web of Science ®Google Scholar
• Carlson DB, Perdew GH. A dynamic role for the Ah receptor in cell signaling? Insights from a diverse group of Ah receptor interacting proteins. J Biochem Mol Toxicol 2002;16(6):317-25
   PubMed Web of Science ®Google Scholar
• Hankinson O. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 1995;35:307-40
   PubMed Web of Science ®Google Scholar
• Mimura J, Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta 2003;1619(3):263-8
   PubMed Web of Science ®Google Scholar
• Androutsopoulos VP, Tsatsakis AM, Spandidos DA. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer 2009;9:187
   PubMed Web of Science ®Google Scholar
• Corchero J, Pimprale S, Kimura S, Gonzalez FJ. Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation. Pharmacogenetics 2001;11(1):1-6
   PubMedGoogle Scholar
• Ueda R, Iketaki H, Nagata K, A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes. Mol Pharmacol 2006;69(6):1924-30
   PubMed Web of Science ®Google Scholar
• Kobayashi A, Sogawa K, Fujii-Kuriyama Y. Cooperative interaction between AhR.Arnt and Sp1 for the drug-inducible expression of CYP1A1 gene. J Biol Chem 1996;271(21):12310-6
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Sueyoshi T, Inoue K, Cytoplasmic accumulation of the nuclear receptor CAR by a tetratricopeptide repeat protein in HepG2 cells. Mol Pharmacol 2003;64(5):1069-75
   PubMed Web of Science ®Google Scholar
• Kawamoto T, Sueyoshi T, Zelko I, Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol 1999;19(9):6318-22
   PubMed Web of Science ®Google Scholar
• Xu RX, Lambert MH, Wisely BB, A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer. Mol Cell 2004;16(6):919-28
   PubMed Web of Science ®Google Scholar
• Suino K, Peng L, Reynolds R, The nuclear xenobiotic receptor CAR: structural determinants of constitutive activation and heterodimerization. Mol Cell 2004;16(6):893-905
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Lecluyse EL, Ferguson SS. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 2007;37(10-11):1196-224
   PubMed Web of Science ®Google Scholar
• Forman BM, Tzameli I, Choi HS, Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature 1998;395(6702):612-5
   PubMed Web of Science ®Google Scholar
• Moore LB, Parks DJ, Jones SA, Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 2000;275(20):15122-7
   PubMed Web of Science ®Google Scholar
• Zelko I, Sueyoshi T, Kawamoto T, The peptide near the C terminus regulates receptor CAR nuclear translocation induced by xenochemicals in mouse liver. Mol Cell Biol 2001;21(8):2838-46
   PubMed Web of Science ®Google Scholar
• Yoshinari K, Kobayashi K, Moore R, Identification of the nuclear receptor CAR:HSP90 complex in mouse liver and recruitment of protein phosphatase 2A in response to phenobarbital. FEBS Lett 2003;548(1-3):17-20
   PubMed Web of Science ®Google Scholar
• Koike C, Moore R, Negishi M. Extracellular signal-regulated kinase is an endogenous signal retaining the nuclear constitutive active/androstane receptor (CAR) in the cytoplasm of mouse primary hepatocytes. Mol Pharmacol 2007;71(5):1217-21
   PubMed Web of Science ®Google Scholar
• Rencurel F, Foretz M, Kaufmann MR, Stimulation of AMP-activated protein kinase is essential for the induction of drug metabolizing enzymes by phenobarbital in human and mouse liver. Mol Pharmacol 2006;70(6):1925-34
   PubMed Web of Science ®Google Scholar
• Honkakoski P, Zelko I, Sueyoshi T, Negishi M. The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol Cell Biol 1998;18(10):5652-8
   PubMed Web of Science ®Google Scholar
• Sueyoshi T, Kawamoto T, Zelko I, The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 1999;274(10):6043-6
   PubMed Web of Science ®Google Scholar
• Madan A, Graham RA, Carroll KM, Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003;31(4):421-31
   PubMed Web of Science ®Google Scholar
• Perrot N, Nalpas B, Yang CS, Beaune PH. Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake. Eur J Clin Invest 1989;19(6):549-55
   PubMed Web of Science ®Google Scholar
• Gerbal-Chaloin S, Daujat M, Pascussi JM, Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem 2002;277(1):209-17
   PubMed Web of Science ®Google Scholar
• Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005;28(3):249-68
   PubMed Web of Science ®Google Scholar
• Honkakoski P, Negishi M. Regulatory DNA elements of phenobarbital-responsive cytochrome P450 CYP2B genes. J Biochem Mol Toxicol 1998;12(1):3-9
   PubMed Web of Science ®Google Scholar
• Makinen J, Frank C, Jyrkkarinne J, Modulation of mouse and human phenobarbital-responsive enhancer module by nuclear receptors. Mol Pharmacol 2002;62(2):366-78
   PubMed Web of Science ®Google Scholar
• Maglich JM, Stoltz CM, Goodwin B, Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 2002;62(3):638-46
   PubMed Web of Science ®Google Scholar
• Goodwin B, Moore LB, Stoltz CM, Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 2001;60(3):427-31
   PubMed Web of Science ®Google Scholar
• Moore JT, Moore LB, Maglich JM, Kliewer SA. Functional and structural comparison of PXR and CAR. Biochim Biophys Acta 2003;1619(3):235-8
   PubMed Web of Science ®Google Scholar
• Goodwin B, Hodgson E, D'Costa DJ, Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol 2002;62(2):359-65
   PubMed Web of Science ®Google Scholar
• Wang H, Faucette S, Sueyoshi T, A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 2003;278(16):14146-52
   PubMed Web of Science ®Google Scholar
• Wortham M, Czerwinski M, He L, Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos 2007;35(9):1700-10
   PubMed Web of Science ®Google Scholar
• Drewes T, Senkel S, Holewa B, Ryffel GU. Human hepatocyte nuclear factor 4 isoforms are encoded by distinct and differentially expressed genes. Mol Cell Biol 1996;16(3):925-31
   PubMed Web of Science ®Google Scholar
• Jiang S, Tanaka T, Iwanari H, Expression and localization of P1 promoter-driven hepatocyte nuclear factor-4alpha (HNF4alpha) isoforms in human and rats. Nucl Recept 2003;1(1):5
   PubMedGoogle Scholar
• Gonzalez FJ. Regulation of hepatocyte nuclear factor 4 alpha-mediated transcription. Drug Metab Pharmacokinet 2008;23(1):2-7
   PubMed Web of Science ®Google Scholar
• Wisely GB, Miller AB, Davis RG, Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. Structure 2002;10(9):1225-34
   PubMed Web of Science ®Google Scholar
• Schroeder F, Huang H, Hostetler HA, Stability of fatty acyl-coenzyme A thioester ligands of hepatocyte nuclear factor-4alpha and peroxisome proliferator-activated receptor-alpha. Lipids 2005;40(6):559-68
   PubMed Web of Science ®Google Scholar
• Kamiyama Y, Matsubara T, Yoshinari K, Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metab Pharmacokinet 2007;22(4):287-98
   PubMed Web of Science ®Google Scholar
• Jover R, Bort R, Gomez-Lechon MJ, Castell JV. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology 2001;33(3):668-75
   PubMed Web of Science ®Google Scholar
• Tirona RG, Lee W, Leake BF, The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 2003;9(2):220-4
   PubMed Web of Science ®Google Scholar
• Rana R, Chen Y, Ferguson S, Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes. Drug Metab Dispos 2010;38(4):591-9
   Google Scholar
• Jones SA, Moore LB, Wisely GB, Kliewer SA. Use of in vitro pregnane X receptor assays to assess CYP3A4 induction potential of drug candidates. Methods Enzymol 2002;357:161-70
   PubMed Web of Science ®Google Scholar
• Zhu Z, Kim S, Chen T, Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J Biomol Screen 2004;9(6):533-40
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Lechon MJ, Houston JB, Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 2007;39(1):159-234
   PubMed Web of Science ®Google Scholar
• Plant N. Strategies for using in vitro screens in drug metabolism. Drug Discov Today 2004;9(7):328-36
   PubMed Web of Science ®Google Scholar
• Sandker GW, Weert B, Olinga P, Characterization of transport in isolated human hepatocytes. A study with the bile acid taurocholic acid, the uncharged ouabain and the organic cations vecuronium and rocuronium. Biochem Pharmacol 1994;47(12):2193-200
   PubMed Web of Science ®Google Scholar
• Silva JM, Morin PE, Day SH, Refinement of an in vitro cell model for cytochrome P450 induction. Drug Metab Dispos 1998;26(5):490-6
   PubMed Web of Science ®Google Scholar
• Smith DA. Induction and drug development. Eur J Pharm Sci 2000;11(3):185-9
   PubMed Web of Science ®Google Scholar
• Roymans D, Annaert P, Van Houdt J, Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metab Dispos 2005;33(7):1004-16
   PubMed Web of Science ®Google Scholar
• LeCluyse EL. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 2001 13(4):343-68
   PubMed Web of Science ®Google Scholar
• LeCluyse E, Madan A, Hamilton G, Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 2000;14(4):177-88
   PubMed Web of Science ®Google Scholar
• Hamilton GA, Jolley SL, Gilbert D, Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions. Cell Tissue Res 2001;306(1):85-99
   PubMed Web of Science ®Google Scholar
• Rodriguez-Antona C, Donato MT, Boobis A, Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 2002;32(6):505-20
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270(1):414-23
   PubMed Web of Science ®Google Scholar
• Parkinson A, Mudra DR, Johnson C, The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004;199(3):193-209
   PubMed Web of Science ®Google Scholar
• Thummel KE, Shen DD, Podoll TD, Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994;271(1):557-66
   PubMed Web of Science ®Google Scholar
• Persson KP, Ekehed S, Otter C, Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans. Pharm Res 2006;23(1):56-69
   PubMed Web of Science ®Google Scholar
• Sinz M, Kim S, Zhu Z, Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 2006;7(4):375-88
   PubMed Web of Science ®Google Scholar
• Westerink WM, Schoonen WG. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 2007;21(8):1581-91
   PubMed Web of Science ®Google Scholar
• Moore LB, Maglich JM, McKee DD, Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol 2002;16(5):977-86
   PubMed Web of Science ®Google Scholar
• Faucette SR, Zhang TC, Moore R, Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007;320(1):72-80
   PubMed Web of Science ®Google Scholar
• van Giersbergen PL, Gnerre C, Treiber A, Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor. Eur J Pharmacol 2002;450(2):115-21
   PubMed Web of Science ®Google Scholar
• Donato MT, Lahoz A, Castell JV, Gomez-Lechon MJ. Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab 2008;9(1):1-11
   PubMed Web of Science ®Google Scholar
• Gripon P, Rumin S, Urban S, Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 2002;99(24):15655-60
   PubMed Web of Science ®Google Scholar
• Aninat C, Piton A, Glaise D, Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 2006;34(1):75-83
   PubMed Web of Science ®Google Scholar
• Kanebratt KP, Andersson TB. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 2008 36(1):137-45
   PubMed Web of Science ®Google Scholar
• Josse R, Aninat C, Glaise D, Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies. Drug Metab Dispos 2008 36(6):1111-8
   PubMed Web of Science ®Google Scholar
• Martin H, Sarsat JP, de Waziers I, Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm Res 2003;20(4):557-68
   PubMed Web of Science ®Google Scholar
• Edwards RJ, Price RJ, Watts PS, Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 2003;31(3):282-8
   PubMed Web of Science ®Google Scholar
• Tateno C, Yoshizane Y, Saito N, Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004;165(3):901-12
   PubMed Web of Science ®Google Scholar
• Emoto C, Yamato Y, Sato Y, Non-invasive method to detect induction of CYP3A4 in chimeric mice with a humanized liver. Xenobiotica 2008;38(3):239-48
   PubMed Web of Science ®Google Scholar
• Katoh M, Tateno C, Yoshizato K, Yokoi T. Chimeric mice with humanized liver. Toxicology 2008;246(1):9-17
   PubMed Web of Science ®Google Scholar
• Azuma H, Paulk N, Ranade A, Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 2007;25(8):903-10
   PubMed Web of Science ®Google Scholar
• Kato M, Chiba K, Horikawa M, Sugiyama Y. The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab Pharmacokinet 2005;20(4):236-43
   PubMedGoogle Scholar
• Fahmi OA, Boldt S, Kish M, Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes. Drug Metab Dispos 2008;36(9):1971-4
   PubMed Web of Science ®Google Scholar
• Kozawa M, Honma M, Suzuki H. Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay. Drug Metab Dispos 2009;37(6):1234-41
   PubMed Web of Science ®Google Scholar
• Kostrubsky VE, Ramachandran V, Venkataramanan R, The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos 1999;27(8):887-94
   PubMed Web of Science ®Google Scholar
• Chang TK, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997;57(10):1946-54
   PubMed Web of Science ®Google Scholar
• Renwick AB, Watts PS, Edwards RJ, Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 2000;28(10):1202-9
   PubMed Web of Science ®Google Scholar
• Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996;24(4):796-801
   PubMed Web of Science ®Google Scholar
• Hsu A, Granneman GR, Witt G, Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997;41(5):898-905
   PubMed Web of Science ®Google Scholar
• Lai AA, Levy RH, Cutler RE. Time-course of interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther 1978;24(3):316-23
   PubMed Web of Science ®Google Scholar
• Faucette SR, Sueyoshi T, Smith CM, Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J Pharmacol Exp Ther 2006;317(3):1200-9
   PubMed Web of Science ®Google Scholar
• Wang H, Faucette S, Moore R, Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem 2004;279(28):29295-301
   PubMed Web of Science ®Google Scholar
• O'Reilly RA. Interaction of chronic daily warfarin therapy and rifampin. Ann Intern Med 1975;83(4):506-8
   PubMed Web of Science ®Google Scholar
• Grub S, Bryson H, Goggin T, The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 2001;57(2):115-21
   PubMed Web of Science ®Google Scholar
• la Porte CJ, Colbers EP, Bertz R, Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004;48(5):1553-60
   PubMed Web of Science ®Google Scholar
• Lau WC, Gurbel PA. Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4. Pharm Res 2006;23(12):2691-708
   PubMed Web of Science ®Google Scholar
• Ernest CS II, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2005;312(2):583-91
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Zhang G, Kenny JR, Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos 2009;37(6):1259-68
   PubMed Web of Science ®Google Scholar
• Liu P, Foster G, Gandelman K, Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007;51(10):3617-26
   PubMed Web of Science ®Google Scholar
• Yakiwchuk EM, Foisy MM, Hughes CA. Complexity of interactions between voriconazole and antiretroviral agents. Ann Pharmacother 2008;42(5):698-703
   PubMed Web of Science ®Google Scholar
• LeCluyse EL, Fix JA, Audus KL, Hochman JH. Regeneration and maintenance of bile canalicular networks in collagen-sandwiched hepatocytes. Toxicol In Vitro 2000;14(2):117-32
   PubMed Web of Science ®Google Scholar
• Kostrubsky VE, Lewis LD, Strom SC, Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. Arch Biochem Biophys 1998;355(2):131-6
   PubMed Web of Science ®Google Scholar
• Masubuchi N, Li AP, Okazaki O. An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chem Biol Interact 1998;114(1-2):1-13
   PubMed Web of Science ®Google Scholar
• Hassett C, Laurenzana EM, Sidhu JS, Omiecinski CJ. Effects of chemical inducers on human microsomal epoxide hydrolase in primary hepatocyte cultures. Biochem Pharmacol 1998;55(7):1059-69
   PubMed Web of Science ®Google Scholar
• Martinez-Jimenez CP, Castell JV, Gomez-Lechon MJ, Jover R. Transcriptional activation of CYP2C9, CYP1A1, and CYP1A2 by hepatocyte nuclear factor 4alpha requires coactivators peroxisomal proliferator activated receptor-gamma coactivator 1alpha and steroid receptor coactivator 1. Mol Pharmacol 2006;70(5):1681-92
   PubMed Web of Science ®Google Scholar
• Dixit V, Hariparsad N, Li F, Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007;35(10):1853-9
   PubMed Web of Science ®Google Scholar
• Bachleda P, Vrzal R, Pivnicka J, Examination of Zolpidem effects on AhR- and PXR-dependent expression of drug-metabolizing cytochromes P450 in primary cultures of human hepatocytes. Toxicol Lett 2009;191(1):74-8
   PubMed Web of Science ®Google Scholar
• Maglich JM, Parks DJ, Moore LB, Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem 2003;278(19):17277-83
   PubMed Web of Science ®Google Scholar
• Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001;299(3):849-57
   PubMed Web of Science ®Google Scholar
• Jigorel E, Le Vee M, Boursier-Neyret C, Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 2006;34(10):1756-63
   PubMed Web of Science ®Google Scholar
• Sahi J, Shord SS, Lindley C, Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes. J Biochem Mol Toxicol 2009;23(1):43-58
   PubMed Web of Science ®Google Scholar
• Ferguson SS, Chen Y, LeCluyse EL, Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol 2005;68(3):747-57
   PubMed Web of Science ®Google Scholar
• Raucy JL, Mueller L, Duan K, Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J Pharmacol Exp Ther 2002;302(2):475-82
   PubMed Web of Science ®Google Scholar
• Chen Y, Kissling G, Negishi M, Goldstein JA. The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4alpha to synergistically activate the human CYP2C9 promoter. J Pharmacol Exp Ther 2005;314(3):1125-33
   PubMed Web of Science ®Google Scholar
• Li T, Chiang JY. Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug Metab Dispos 2006;34(5):756-64
   PubMed Web of Science ®Google Scholar
• Assem M, Schuetz EG, Leggas M, Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 2004;279(21):22250-7
   PubMed Web of Science ®Google Scholar
• Fang HL, Strom SC, Ellis E, Positive and negative regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) gene transcription by rifampicin: roles of hepatocyte nuclear factor 4alpha and pregnane X receptor. J Pharmacol Exp Ther 2007;323(2):586-98
   PubMed Web of Science ®Google Scholar
• Li L, Stanton JD, Tolson AH, Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res 2009;26(4):872-82
   PubMed Web of Science ®Google Scholar
• Kast HR, Goodwin B, Tarr PT, Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002;277(4):2908-15
   PubMed Web of Science ®Google Scholar
• Peamkrasatam S, Sriwatanakul K, Kiyotani K, In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. Drug Metab Pharmacokinet 2006;21(6):475-84
   PubMed Web of Science ®Google Scholar
• Elsherbiny DA, Asimus SA, Karlsson MO, A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharmacokinet Pharmacodyn 2008;35(2):203-17
   PubMed Web of Science ®Google Scholar
• Simonsson US, Jansson B, Hai TN, Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther 2003;74(1):32-43
   PubMed Web of Science ®Google Scholar
• Svensson US, Ashton M, Trinh NH, Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther 1998;64(2):160-7
   PubMed Web of Science ®Google Scholar
• Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004;43(15):1089-115
   PubMed Web of Science ®Google Scholar
• Parker AC, Pritchard P, Preston T, Choonara I. Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. Br J Clin Pharmacol 1998;45(2):176-8
   PubMed Web of Science ®Google Scholar
• Herman D, Locatelli I, Grabnar I, The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol 2006;62(4):291-6
   PubMed Web of Science ®Google Scholar
• Ketter TA, Jenkins JB, Schroeder DH, Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995;15(5):327-33
   PubMed Web of Science ®Google Scholar
• Backman JT, Olkkola KT, Ojala M, Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996;37(3):253-7
   PubMed Web of Science ®Google Scholar
• Furukori H, Otani K, Yasui N, Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. Neuropsychopharmacology 1998;18(5):364-9
   PubMed Web of Science ®Google Scholar
• McCune JS, Hawke RL, LeCluyse EL, In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 2000;68(4):356-66
   PubMed Web of Science ®Google Scholar
• Fellay J, Marzolini C, Decosterd L, Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol 2005;60(12):865-73
   PubMed Web of Science ®Google Scholar
• Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 2005;97(3):125-34
   PubMed Web of Science ®Google Scholar
• Reed GA, Peterson KS, Smith HJ, A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol Biomarkers Prev 2005;14(8):1953-60
   PubMed Web of Science ®Google Scholar
• Ma Q, Lu AY. CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab Dispos 2007;35(7):1009-16
   PubMed Web of Science ®Google Scholar
• Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 2005;39(3):307-12
   PubMed Web of Science ®Google Scholar
• Huuskonen P, Storvik M, Reinisalo M, Microarray analysis of the global alterations in the gene expression in the placentas from cigarette-smoking mothers. Clin Pharmacol Ther 2008;83(4):542-50
   PubMed Web of Science ®Google Scholar
• Chang TK, Chen J, Pillay V, Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. Toxicol Sci 2003;71(1):11-9
   PubMed Web of Science ®Google Scholar
• Landay RA, Gonzalez MA, Taylor JC. Effect of phenobarbital on theophylline disposition. J Allergy Clin Immunol 1978;62(1):27-9
   PubMed Web of Science ®Google Scholar
• Jao JY, Jusko WJ, Cohen JL. Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res 1972;32(12):2761-4
   PubMed Web of Science ®Google Scholar
• Heinemeyer G, Gramm HJ, Simgen W, Kinetics of hexobarbital and dipyrone in critical care patients receiving high-dose pentobarbital. Eur J Clin Pharmacol 1987;32(3):273-7
   PubMed Web of Science ®Google Scholar
• Back DJ, Bates M, Bowden A, The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 1980;22(5):495-503
   PubMed Web of Science ®Google Scholar
• Miller M, Cosgriff J, Kwong T, Morken DA. Influence of phenytoin on theophylline clearance. Clin Pharmacol Ther 1984;35(5):666-9
   PubMed Web of Science ®Google Scholar
• Slattery JT, Kalhorn TF, McDonald GB, Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996;14(5):1484-94
   PubMed Web of Science ®Google Scholar
• Lim ML, Min SS, Eron JJ, Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr 2004;36(5):1034-40
   PubMed Web of Science ®Google Scholar
• Backman JT, Granfors MT, Neuvonen PJ. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol 2006;62(6):451-61
   PubMed Web of Science ®Google Scholar
• Loboz KK, Gross AS, Williams KM, Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther 2006;80(1):75-84
   PubMed Web of Science ®Google Scholar
• Bidstrup TB, Stilling N, Damkier P, Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol 2004;60(2):109-14
   PubMed Web of Science ®Google Scholar
• Jaakkola T, Backman JT, Neuvonen M, Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol 2006;61(1):70-8
   PubMed Web of Science ®Google Scholar
• Park JY, Kim KA, Kang MH, Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004;75(3):157-62
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Fromm MF, Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003;42(9):819-50
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001;69(6):400-6
   PubMed Web of Science ®Google Scholar
• Kanebratt KP, Diczfalusy U, Backstrom T, Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther 2008;84(5):589-94
   PubMed Web of Science ®Google Scholar
• Holtbecker N, Fromm MF, Kroemer HK, The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 1996;24(10):1121-3
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2000;68(5):495-500
   PubMed Web of Science ®Google Scholar
• Villikka K, Kivisto KT, Luurila H, Neuvonen PJ. Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther 1997;62(6):629-34
   PubMed Web of Science ®Google Scholar
• Yeh RF, Gaver VE, Patterson KB, Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42(1):52-60
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 2008;52(5):1663-9
   PubMed Web of Science ®Google Scholar
• Jiang X, Blair EY, McLachlan AJ. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol 2006;46(11):1370-8
   PubMed Web of Science ®Google Scholar
• Wang LS, Zhou G, Zhu B, St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004;75(3):191-7
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Donovan JL, DeVane CL, Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290(11):1500-4
   PubMed Web of Science ®Google Scholar
• Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003;73(1):41-50
   PubMed Web of Science ®Google Scholar
• Birkett DJ, Miners JO, Attwood J. Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction. Br J Clin Pharmacol 1983;15(5):567-9
   PubMed Web of Science ®Google Scholar
• Wing LM, Miners JO, Lillywhite KJ. Verapamil disposition--effects of sulphinpyrazone and cimetidine. Br J Clin Pharmacol 1985;19(3):385-91
   PubMed Web of Science ®Google Scholar
• Yoshinari K, Yoda N, Toriyabe T, Yamazoe Y. Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5′-flanking region. Biochem Pharmacol 2010;79(2):261-9
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Nakajima M, Yokoi T. Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene. J Biochem 2003;133(5):583-92
   PubMed Web of Science ®Google Scholar
• Chen Y, Ferguson SS, Negishi M, Goldstein JA. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol Pharmacol 2003;64(2):316-24
   PubMed Web of Science ®Google Scholar